Best-practice recommendations for autoimmune encephalitis emphasize that diagnosis is clinical and should not wait for antibody results when the syndrome is strongly suggestive. New-onset seizures, psychiatric symptoms, cognitive change, movement disorders or autonomic instability can occur in different combinations, and MRI and EEG help identify supportive patterns while cerebrospinal-fluid analysis helps assess inflammatory and infectious alternatives. The guidance recommends considering empiric immunotherapy when clinical suspicion is high after appropriate exclusion of major mimics. For internists and neurologists, the challenge is balancing urgency with diagnostic discipline. Infectious encephalitis, metabolic disorders, toxic exposures and neoplastic processes may present similarly, and indiscriminate immunosuppression can be harmful. The publication therefore provides a practical framework for sequencing investigations, involving neurology early and screening for an associated tumor when the phenotype warrants it. First-line immunotherapy commonly includes corticosteroids with or without IVIG or plasma exchange, while second-line therapy may be considered when there is inadequate response. The key teaching point is that timely recognition matters because delay in treatment can worsen neurologic outcomes.